Skip to content
drillr.ai
Sign up

CRBU

Caribou Biosciences, Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.42
−5.82%
Ask drillr

  • Oct 7, 2026, 14:13 UTC

    Caribou Biosciences, Inc. shares fell 49.30% to $0.58.

    Source:

  • Oct 7, 2026, 12:56 UTC

    Caribou Biosciences, Inc. is shutting down after failing to raise the funds needed for a late-stage clinical trial of its off-the-shelf CAR-T lymphoma therapy.

    Source:

  • Oct 6, 2026, 20:14 UTC

    Caribou Biosciences reported the departure of Chief Financial Officer Sriram Ryali; the effective date was not disclosed.

  • Oct 6, 2026, 20:05 UTC

    Caribou Biosciences, Inc. announced that it will evaluate strategic alternatives to maximize stockholder value.

    Source:

  • Oct 6, 2026, 20:05 UTC

    Caribou Biosciences, Inc. said it plans to discontinue its vispa-cel and CB-011 allogeneic CAR-T cell therapy programs.

    Source:

  • Aug 13, 2026, 23:06 UTC

    Caribou Biosciences, Inc. reported a Q2 2026 net loss of $0.24 per share, narrower than the Zacks Consensus Estimate of a $0.33 loss and improved from a $0.35 loss a year earlier.

    Source:

  • Aug 13, 2026, 00:00 UTC

    Olema Pharmaceuticals appointed Jason O'Byrne as Chief Financial Officer, principal financial officer and principal accounting officer, effective as of the announcement date.

  • Jun 11, 2026, 12:00 UTC

    Caribou Biosciences presented phase 1 clinical data for its CAR-T cell therapy candidate vispacabtagene regedleucel (vispa-cel) at the 2026 European Hematology Association Annual Meeting, showing a median progression-free survival of 17.1 months in second-line large B cell lymphoma patients.

    Source: